ADC Therapeutics (ADCT) Research & Development: 2019-2023
Historic Research & Development for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to $27.1 million.
- ADC Therapeutics' Research & Development rose 164.98% to $27.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $18.9 million, marking a year-over-year increase of 113.57%. This contributed to the annual value of -$187,898 for FY2022, which is 18.92% down from last year.
- ADC Therapeutics' Research & Development amounted to $27.1 million in Q3 2023, which was down 13.60% from $31.3 million recorded in Q2 2023.
- ADC Therapeutics' 5-year Research & Development high stood at $35.4 million for Q1 2020, and its period low was -$49.0 million during Q1 2022.
- Moreover, its 3-year median value for Research & Development was -$39.2 million (2021), whereas its average is -$21.4 million.
- In the last 5 years, ADC Therapeutics' Research & Development tumbled by 105,184.70% in 2020 and then soared by 164.98% in 2023.
- ADC Therapeutics' Research & Development (Quarterly) stood at -$30,424 in 2019, then plummeted by 105,184.70% to -$32.2 million in 2020, then decreased by 14.46% to -$42,492 in 2021, then declined by 14.69% to -$48,733 in 2022, then skyrocketed by 164.98% to $27.1 million in 2023.
- Its Research & Development stands at $27.1 million for Q3 2023, versus $31.3 million for Q2 2023 and -$39.5 million for Q1 2023.